A multicentre prospective study response to treatment in genotype 3 and 1b infected patients with sickest liver cirrhosis: SVR 4 is not a reliable measure
Marcello Persico(University of Salerno), Savino Bruno, Vincenza Calvaruso(University of Palermo), Maria Rendina, Andrea Aglitti(University of Salerno), V. Di Marco(University of Palermo), Ana Lleò(Humanitas University), Alessio Aghemo, Fabio Conti, Alfredo Di Leo(University Gastroenterology), Alessia Ciancio(Department of Medical Sciences), Alessia Giorgini(Università Cattolica del Sacro Cuore), Pietro Andreoné, B. Coco(Azienda Ospedaliera Universitaria Pisana), Yumi Toshina(University of Turin), Maurizia Rossana Brunetto(University of Pisa), Luca Marzi(Azienda Ospedaliero-Universitaria di Modena), Massimo Zuin(AOL (United States)), S. Bollani(Azienda Ospedaliera Fatebenefratelli e Oftalmico), Erica Villa(University of Modena and Reggio Emilia), Stella De Nicola(Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico)
Cited by 0
Related Papers
Obeticholic acid for the treatment of non-alcoholic steatohepatitis: interim analysis from a multicentre, randomised, placebo-controlled phase 3 trial
|The Lancet|2019|1.2k
A Placebo-Controlled Trial of Obeticholic Acid in Primary Biliary Cholangitis
|New England Journal of Medicine|2016|1.1k
Global change in hepatitis C virus prevalence and cascade of care between 2015 and 2020: a modelling study
|The Lancet. Gastroenterology & hepatology|2022|664
Role of Oxidative Stress in Pathophysiology of Nonalcoholic Fatty Liver Disease
|Oxidative Medicine and Cellular Longevity|2018|643
Accelerating the elimination of viral hepatitis: a Lancet Gastroenterology & Hepatology Commission
|The Lancet. Gastroenterology & hepatology|2019|539